phase readout

NCT05272384: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

RECRUITINGupdated 6m ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE1. Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma

view source ↗

NCT05272384: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Report a data issue

comments(0)